Home
About
Market Pulse
Stock Of the Day
Swing Trading
Stock Analysis
Investors Corner
Stock Market Today
Barron's
Barron's RTA
How I Made $5000 in the Stock Market
Biotech and Pharma
Why Ultragenyx Stock Dropped 42% and What Comes Next
为什么乌尔特拉基因药业股票暴跌42%，接下来会发生什么？
This Beaten-Down Pharma Stock Could Make a Turnaround in the New Year
这只被压低估值的制药股有望在新的一年迎来反转
This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion.
这家生物技术股票飙升赛诺菲将以22亿美元收购它
Wegovy Pill Approval Sends Novo Nordisk Stock Soaring. What It Means for Eli Lilly.
Wegovy片剂获批推动诺和诺德股价飙升这对礼来意味着什么
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.
这家制药股去年表现惨淡为何一位分析师认为它有望上涨250%
Lilly Shares Have Tripled on Weight-Loss Drugs. Why the Stock Looks Cheap.
莉莉股价因减肥药三倍上涨为何这只股票看起来便宜
White House Cuts Drug-Pricing Deals With Pharma Companies, Tilting System Toward Self-Pay
白宫与制药公司达成药物定价协议，使体系向自付模式倾斜
BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.
BioMarin以近50亿美元收购罕见病生物技术公司股价飙升
Lose Weight on Zepbound, Keep It Off With Eli Lilly’s New Pill? Data Say That Works.
在Zepbound上减重，用 Eli Lilly 的新药维持体重不反弹？数据表明这可行
Insmed Stock Plummets 19%. This Is What Sparked the Selloff.
Insmed股价暴跌19%是什么引发了抛售？
Pfizer CEO Defends Vaccines, Promises Growth by End of Decade
辉瑞CEO辩护疫苗，承诺十年末实现增长
Novo Nordisk Is Selling Ozempic for $24 a Week in India. Why It’s So Cheap.
诺和诺德正在印度以每周24美元的价格销售奥司明为什么这么便宜
Eli Lilly’s Latest Obesity Drug Delivers Strong Results. It Might Work Too Well.
Eli Lilly最新减肥药表现强劲但或许效果过于理想
Cancer Study Buoys These Small Biotechs
癌症研究提振这些小型生物技术公司
Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.
辉瑞转向中国寻求减肥药试验国会担忧中国生物科技公司
Obesity Biotechs’ Gains Hit Shares of Eli Lilly, Novo Nordisk
肥胖生物技术公司的业绩提振了艾尔利和诺和诺德的股价
Kymera Therapeutics Stock Heads for Record. Why Investors Are Excited About Its Anti-Inflammatory Drug.
Kymera Therapeutics 股价飙升至历史新高投资者为何对它的抗炎药物充满期待
FDA 更多人事变动引发前领导层反对
More Changes at FDA Prompt Pushback From Former Leaders
The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch.
生物科技行业比投资者想象的更健康这些股票值得关注
Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s Down 50%.
Janux Therapeutics 股价暴跌后发布“积极”癌症数据，为何下跌50%
Moderna and Novavax Stocks Drop as FDA Outlines Stricter Vaccine Approvals
Moderna和Novavax股价下跌，因FDA拟收紧疫苗审批标准
FDA批准令诺华基因疗法迎来更大市场
Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.
诺和诺德股价因减肥药物数据积极而上涨为何它值得更好的回报
Novo Nordisk Stock Falls. Why Its Alzheimer’s Trial News Is Hitting Shares.
Novo Nordisk’s Alzheimer’s Trials Were a Long Shot. Their Failure Is Still Hitting the Stock.
诺和诺德的阿尔茨海默病临床试验本就是一场豪赌其失败的影响至今仍在股价上体现
诺和诺德股价下跌其阿尔茨海默病临床试验结果为何冲击股价
Eli Lilly Stock Closes Above $1 Trillion After Climbing $400 Billion in 3 Months
Eli Lilly’s Market Cap Breaks $1 Trillion After Climbing $400 Billion in 3 Months
礼来公司市值突破1万亿美元，三个月内涨幅超4000亿美元
礼来股价在三个月内上涨4000亿美元，收盘市值突破1万亿美元
This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.
这家药企太便宜了，不容忽视为何选择买入勃林格殷格翰
Moderna Trims Pipeline and Takes On $1.5 Billion Loan as Cash Worries Loom
莫德纳缩减研发管线并借入15亿美元贷款以应对现金困境
A Sickle Cell Trial Delivers Mixed Results. Agios Stock Falls by 48%.
镰刀型贫血症临床试验结果Mixed ResultsAgios股价下跌48%
Merck Stock Rises as Heart-Drug Test Offers Hope for Post-Keytruda Era
默克股价上涨，心药试验为Keytruda时代后带来希望
Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It’s a Worry for the Stocks.
诺华与礼来减肥药价格战升温，这对股价构成担忧
Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.
爵士制药公司和zymeworks公布抗癌治疗积极成果股价飙升
Bristol Myers Shares Sink on Yet Another Trial Failure
Bristol Myers 股价因又一项临床试验失败而下跌
Merck Is Paying Up for Flu Biotech as M&A Spree Continues
默克为流感生物技术公司支付高价，并购潮持续
The FDA Has a New Drug Chief. What it Means for Biotech Stocks.
美国FDA任命了新任药物主管这对生物科技股票意味着什么
Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients
默克公司的心脏药片在试验患者中显著降低胆固醇水平
Eli Lilly Stock on Pace for a New High. The Zepbound Maker Just Got a Big Upgrade.
礼来公司股价正朝着新高迈进这款泽布替尼的制造商刚刚获得重大利好
Cogent Biosciences Stock Surges 136%. Investors See Promise in Its Cancer Drug.
科根生物科学公司股价飙升136%投资者看好其抗癌药物的前景
Pfizer Wins Battle for Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.
辉瑞赢得与减肥药企Metsera的争夺战诺和诺德才是真正的赢家
Intellia Therapeutics Says a Patient Died in Gene Editing Trial
Novo Nordisk and Eli Lilly Can Sell Their Weight-Loss Drugs to Medicare Market
Moderna Is Running Low on Cash. Its Earnings Are Thursday.
iRhythm: The Heart Monitor Maker Whose Stock Keeps Beating
Novo Nordisk Stock Falls After Earnings. It Cut Guidance on These Fears.
Sarepta Stock Tumbles 34% After Earnings Report. Why Shares Crashed.
Pfizer Stock Slips. Under the Surface, Earnings Weren’t Great.
UniQure Stock Plummets 52% on Potential FDA Decision. Here’s Why.
UniQure Stock Plummets 67% on Potential FDA Decision. Here’s Why.
AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.
Vertex Pharma’s Stock Has Tumbled. Earnings Will Stop the Pain.
Gilead Earnings Beat Expectations. The Stock Is Still Falling.
Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.
Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal
Merck Stock Falls. Sales of Key Products Missed Estimates.
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 22%.
Novartis’ Avidity Deal Is a Green Light for Biotech Rally
A GSK Cancer Drug Is Making a Comeback. It’s So-So News for the Stock.
Medpace Holdings’ Good Quarter Is Another Sign Biotech Is Back
Wall Street Wonders if Grail’s Cancer Test Results Are a True Positive
Novo Nordisk’s Entire Board Is Stepping Down in a Surprise Move. Here’s Why.
Grail Blood Test Found Seven Times More Cancers Than Standard Tests, Data Show
Biotech Is Finally Rallying. Why Mizuho’s Jared Holz Is Optimistic This Time.
Eli Lilly, Novo Nordisk Stocks Drop. Trump Targets Ozempic, ‘Fat Loss’ Drug Prices.
Roche Sets Gene-Sequencing Record. It’s a Challenge for Illumina.
A Treatment for Tremors Is Back From the Dead. This Stock Is Up 200%.
Top Novavax Shareholder Demands Company’s Sale
Johnson & Johnson Earnings Beat Estimates. Why the Stock Is Dropping.
Trump’s AstraZeneca Deal Echoes Pfizer Pact. Big Pharma’s Political Headaches Are Easing.
Biotech Stocks Have Struggled Since 2021. Why They’re Coming Back.
AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising.
Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.
A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here’s Who It Is.
A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here’s Who It Is.
Neogen Stock Spikes 23% After Earnings. Cost Cuts Will Include Layoffs.
Former Top FDA Official, Forced Out by Kennedy, Lands at Eli Lilly
This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.
Biotech Stocks Are Up. The Sector Is Looking Better Than It Has in Years.
Novo Nordisk Is Ready for Another Round of the Weight-Loss-Drug Wars
Buy Novo Nordisk Stock as Health Names Return to Favor, Analyst Says
Gilead’s Lost Decade Is Over. It’s Time to Buy the Stock.
Trump Triggered a Rally in Drug Stocks. Why It Might Not Last.
Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.
Pfizer Stock Soars on Trump’s New Drug Pricing Plan. Here’s Why.
GSK Will Replace CEO Walmsley With a Company Insider. The Stock Is Up.
Novo Nordisk Stock Is Downgraded. There’s a ‘Tough Path Ahead.’
MoonLake Immunotherapeutics Stock Collapses. Why It’s Down 88%.
This Dutch Drugmaker’s Stock Is Jumping 38%. Here’s Why It’s Being Acquired.
Novo, Lilly Weight-Loss Drugs May Help Alzheimer’s Patients. What It Means for the Stocks.
Deadline Comes Today in Trump’s Big Drug Pricing Initiative
Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.
Guardant’s New Blood Test Can Detect Many Different Cancers. The Company Is Promising the Same for Other Diseases.
Why One Top International Fund Likes Novo Nordisk Stock
Why One Top International Fund Likes Novo Nordisk Stock
Kenvue Stock Rebounds After Trump Links Tylenol to Autism. Here’s Why.
Pfizer Jumps Back into the Weight-Loss Race With $4.9B Acquisition
89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion.
Novo Nordisk Stock Jumps. What the Latest Ozempic Data Show.
Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says
Data on Eli Lilly’s Weight Loss Pill Haven’t Thrilled Investors. New Updates Are Complicating the Picture.
GSK Says It Will Spend $30B on U.S. Manufacturing and R&D
Novo Nordisk Needs a Better Obesity Pipeline. Its Newest Data Looks Ho-Hum.
Novo Nordisk Stock Rises. Its Diabetes Pill Cleared a Key Hurdle.
Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock
Vaccine Stocks Fall on Reports FDA Will Allege Link Between Covid-19 Shots and Child Deaths
Novartis Catches a ‘Sell.’ Goldman Sachs Says the Stock Is Overvalued.
AbbVie Stock Hit a Record on ‘Big Win’ for Blockbuster Drug. The Case for Buying In.
Pfizer Is Growing More Reliant on Vaccines as Controversies Swirl
Pfizer Is Growing More Reliant on Vaccines as Controversies Swirl
More Blood Tests for Cancer Hit the Market
Trump’s Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.
Novo Nordisk Cuts 9,000 Jobs and Slashes Guidance. Why the Stock Is Rising.
A Lyme Disease Vaccine’s Final Test Results Could Appear By Yearend.
This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It.
Amid Vaccine Controversy, Pfizer Says New Covid Shots Are Effective
FDA Approves Pfizer Covid Vaccine but Adds Restrictions on Its Use
Eli Lilly Stock Rises. Its Pill Has Ramped Up the Weight-Loss War With Novo Nordisk.
Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.
Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.
This Weight-Loss Stock Fell More Than 30%. What Sent It Crashing.
This Weight-Loss Stock Is Down 40%. It Lowers the Risks for Eli Lilly and Novo Nordisk.
Nvidia Planning New AI Chip for China, Says Report. What It Means for the Stock.
Nvidia Stock Drops 3.5%. Here’s Why Shares Were Down So Much Today.
A Tweak to Medicare is Good for Merck. Can It Cure the Troubled Stock?
Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings, at $499 Per Month. Why GoodRx Stock Spikes.
Wegovy News Pushes Novo Nordisk Stock Higher
Vertex Pharma CEO Buys the Stock Dip
Vertex Pharma CEO Buys the Stock Dip
Novo Nordisk Stock Could Benefit From Eli Lilly’s Weight-Loss Price Hikes
Big Pharma Has a New Vision for Selling Drugs. It’s Going to the Mattresses.
Big Pharma Has a New Vision for Selling Drugs. It’s Going to the Mattresses.
Moderna Stock Jumps as NIH Chief Tempers Administration’s Attack on mRNA
Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data
Leadership Turmoil at FDA Adds to Difficult Stretch for Biotech Investors
Did Eli Lilly Stock Just Have Its Novo Nordisk Moment?
Gilead Earnings Beat Estimates, But All Eyes Are on a New HIV Shot
Eli Lilly Stock Dives After Earnings Beat. Here’s Why.
RFK Jr. Ordered the HHS to Stop Funding mRNA Vaccine Development. The Edict Hit a Biotech Working on an Unrelated Treatment.
Novo Nordisk Stock Is Dropping After Earnings. It Got Worse.
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason.
Vertex Stock Tumbles After Strong Earnings. What’s Spooking Investors.
Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain.
BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped.
Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem.
Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping.
Trump Talks Tough on Drug Prices but His Demands Have Softened
Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
AbbVie Stock Pops After Earnings. What’s Driving Shares Higher.
Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.
Top FDA Official’s Surprise Departure Means More Uncertainty for Biotech
Novo Nordisk Stock Got Battered. Think Twice Before Buying the Dip.
The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%.
Sarepta Stock Just Soared 40%. Here’s Why.
Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.
Sarepta Stock Rises Despite Downgrade and FDA Probe. The Crisis Explained.
Europe’s Pharma Stocks Look Cheap but Tariffs Cloud the Outlook
Europe’s Pharma Stocks Look Cheap but Tariffs Cloud the Outlook
This Weight-Loss Stock Sank After Earnings. It’s Still a Risk for Eli Lilly, Novo Nordisk.
Sarepta’s Troubles Show Risk, Investor Opportunity in Biotech Convertible Bonds
Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment
This Clinical Trials Stock Just Soared 50%. What Caused It to Pop.
Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.
Sarepta Stock Is Falling. How Its Crisis Went From Bad to Worse.
Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target
Sarepta Shares Crash on Report That FDA Will Ask It to Stop Shipping Key Drug
Sarepta Makes Big Cuts After Patient Deaths. Its Prospects Remain Uncertain.
Boston Scientific Stock Is on Pause. Its Earnings Could Get It Moving Higher Again.
Trump Threatens Pharma Tariffs Soon. Why the Stocks Are Looking Healthy.
Johnson & Johnson Beats Earnings Estimates. CFO Says It Can Do Any Deal It Wants.
Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.
Eli Lilly Has Seized the Lead in Anti-Obesity Drugs. Next Up: a Pill.
Eli Lilly Has Seized the Lead in Anti-Obesity Drugs. Next Up: a Pill.
Biotech Stock Ultragenyx Is Falling on Unsatisfying Trial Update
Merck Is Buying Lung-Disease Biotech in $10 Billion Deal
Moderna Stock Is Climbing. It Has Been a Tumultuous Few Days for Pharma.
Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.
Kennedy Expands RSV Vaccine Recommendations. Moderna, Pfizer Shares Are Up.
Moderna Stock Is Climbing on Trial Data. A Flu-Covid Vaccine Isn’t a Sure Thing.
Two Beaten-Down Biotech Stocks See Big Insider Buys
Two Beaten-Down Biotech Stocks See Big Insider Buys